Equities

Dswiss Inc

DQWS:PKC

Dswiss Inc

Actions
  • Price (USD)9.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

DSwiss, Inc. is a beauty supply company. The Company sells cosmetics and other related beauty products to consumers in Malaysia with focus to expand around the world. The Company, through its subsidiaries, supplies beauty products directly to clients. The Company operates through two segment in Malaysia and Hong Kong. The Company's beauty supplies include beverages to assist in burning and reducing fat, anti-aging creams, and products designed to improve the overall health and physical appearance of its clients. The Company's subsidiaries include DSwiss Holding Limited, which is engaged in investment holding, and its DSwiss (HK) Limited and DSwiss Sdn Bhd are engaged in supply of beauty products. The Company has a domain, www.dswissbeauty.com. The Company's products include Coffee Plus, Kiwi Cell Detox, Triple Stem Cell, Silk Mask, Coffee Slimming Scrub and Peppermint Slimming Gel.

  • Revenue in USD (TTM)1.35m
  • Net income in USD7.67k
  • Incorporated2015
  • Employees6.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Astrazeneca Pharma India Ltd108.90m10.31m1.31bn1.33k127.07--101.7312.0430.2430.24319.28--------6,024,223.00--7.27--14.2062.6560.239.475.48--82.71--0.0014.219.9832.62---9.79--
Mayinglong Pharmaceutical Group Co Ltd515.35m66.33m1.35bn3.09k20.382.94--2.620.99050.99057.706.860.89126.7821.791,073,238.0011.9610.2115.0412.6838.1142.1113.4212.913.85--0.077732.213.199.3716.4213.42-18.198.45
Heron Therapeutics Inc83.26m-228.31m1.41bn223.00--6.45--16.94-2.51-2.510.91472.150.21080.89772.27373,345.30-57.81-64.47-77.11-86.8058.2362.24-274.23-285.212.28--0.0371---39.28---11.00--44.38--
Luckwel Pharmaceuticals Inc0.00-366.21k1.43bn-----------0.0026-0.00260.00-0.00820.00-------808.95-726.38-------------------------15.91------
The United Laboratories Intl. Hldgs Ltd.1.36bn108.98m1.59bn13.00k14.181.197.771.170.47190.47195.985.640.57223.313.31812,611.404.572.477.254.2043.3940.297.994.881.403.030.204324.074.537.069.5451.04-3.00--
Clinigen Group PLC731.26m18.19m1.59bn25.0089.232.5816.072.170.0950.0953.883.290.50165.724.1420,748,000.001.251.851.492.4540.9738.592.493.201.336.750.486258.0210.3722.29163.4619.2321.6517.48
Guangxi Wuzhou Zhongheng Group Co.,Ltd597.61m91.30m1.64bn3.99k17.981.55--2.750.16910.16911.111.960.37921.306.74963,400.102.947.174.278.8382.8781.937.7618.531.72--0.158140.58-3.6122.31-24.451.59-13.23-4.51
Zhejiang CONBA Pharmaceutical Co., Ltd.904.36m49.53m1.84bn9.52k35.712.24--2.030.1240.1242.271.980.60952.004.26611,494.904.454.657.667.3962.9367.327.307.201.01--0.246852.38-12.702.19231.150.58059.92--
DSwiss Inc1.35m7.67k1.86bn6.00225,000.00--39,352.101,381.700.000040.000040.0065-0.00053.7935.52154.11224,620.007.65-52.17---124.4227.2733.272.02-66.690.527349.09----392.4854.12102.69---14.05--
Data as of --. Currency figures normalised to Dswiss Inc's reporting currency: US Dollar USD
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.